ClinicalTrials.gg
CompletedNCT00332436Updated May 30, 2011

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

A Phase 3 interventional study of brimonidine/timolol fixed combination in Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-30.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
586
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Ocular Hypertension by AbbVie — none open to participants now, 1 under way, none of them phase 3. Ocular Hypertension · AbbVie.

Enrollment
8th of 58
586 · median 215
Started
1999
with 1 other
Phase 3
22 of 80
none open now
Registered
3rd of 80
by date

Among the 80 studies in Ocular Hypertension by AbbVie, this one is the 8th largest by enrollment of the 58 interventional ones that give a count, is one of 2 that started in 1999, is one of 22 in phase 3, and was the 3rd registered.

Ocular Hypertension

659 studies on the registry are indexed under Ocular Hypertension; 48 are open to participants now.

Browse Ocular Hypertension studies →

Open to participants now

None of the 80 studies in Ocular Hypertension by AbbVie is open now. The open studies under Ocular Hypertension, anywhere →

Who these studies take

Of the 36 Ocular Hypertension studies recruiting now, 31 (86%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 80 studies in Ocular Hypertension by AbbVie as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

03

Conditions studied

  • Ocular Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes
  • Patient requires IOP-lowering drug in both eyes

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled medical condition
  • to beta-adrenoceptor antagonist or brimonidine therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
586 participants (actual)

Interventions

  • Drugbrimonidine/timolol fixed combination
06

What researchers measure

Primary outcomes

  1. IOP

07

Study locations

1 site
  • Louisville, Kentucky, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 1999, a primary completion of Nov 2001 and a completion of Nov 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2006
First posted
Jun 1, 2006
Start
Dec 1999
Primary completionActual
Nov 2001
CompletionActual
Nov 2001
Last update
May 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00332436
Lead sponsor
Allergan
First posted
Jun 1, 2006
Start date
Dec 1999
Primary completion
Nov 2001
Completion
Nov 2001
Last update
May 30, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion